• Explore /
  • Poster
  • / Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.

Abstract Video & Slides Poster

Authors

null

Thomas Powles

Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew’s Hospital, London, United Kingdom

Thomas Powles , Daniel P. Petrylak , Se Hoon Park , Srikala S. Sridhar , Claudia Caserta , Antoine Thiery Vuillemin , Hyo Jin Lee , Joaquim Bellmunt , Yoshiaki Yamamoto , Jeanny B. Aragon-Ching , Bo Huang , Keith A. Ching , Craig B. Davis , Alessandra Di Pietro , Yohann Loriot , Petros Grivas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT02603432

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4520)

DOI

10.1200/JCO.2021.39.15_suppl.4520

Abstract #

4520

Abstract Disclosures

Similar Posters

First Author: Petros Grivas

First Author: Norihiko Tsuchiya

First Author: Srikala S. Sridhar

First Author: Philippe Barthelemy